Crude (n = 53) | Adjusted* (n = 48) | |||||
---|---|---|---|---|---|---|
Model 1 | Model 2 | |||||
HR [CI 95%] | p (Wald) | HR [CI 95%] | p (Wald) | HR [CI 95%] | p (Wald) | |
Gender | ||||||
Men | 2.36 [0.69–8.07] | 0.17 | 2.23 [0.63-7.84] | 0.21 | 3.9 [0.59-26.81] | 0.16 |
Women | 1 | 1 | 1 | |||
Age (years) ** | 0.97 [0.93-1.02] | 0.25 | 0.95 [0.90-1.01] | 0.09 | 0.94 [0.89-0.99] | 0.03 |
Adverse drug events (ADE) | ||||||
Yes | 0.39 [0.09-1.74] | 0.22 | - | - | - | - |
No | 1 | - | - | - | - | |
Duration of primaquine therapy | ||||||
Short regimen | 1 | 0.18 | 1 | 0.14 | 1 | 0.04 |
Long regimen | 0.46 [0.15-1.42] | 0.42 [0.13-1.33] | 0.28 [0.08-0.98] | |||
Primaquine total dose adjusted by weight | ||||||
Yes (≥ 3.2 mg/kg) | 1 | 0.03 | 1 | 0.04 | - | - |
No (< 3.2 mg/kg) | 2.94 [1.09-8.33] | 3.13 [1.08-9.09] | - | - | ||
Primaquine total dose (mg/kg) | ||||||
< 3.6 | 5.24 [0.68-40.15] | 0.24 | - | - | 9.36 [1.06-82.23] | 0.04 |
3.6 – 4.1 | 1 | - | - | 1 | ||
> 4.1 | 7.09 [0.64-78.74] | - | - | 15.4 [0.79-300.57] | 0.07 | |
Concordance | - | - | 0.73 | 0.75 | ||
R square | - | - | 0.23 | 0.28 | ||
p (Wald) | - | - | 0.06 | 0.08 |